Natural History Study for Achromatopsia

Status Completed

Clinical Trial Summary

In preparation for human clinical trials we intend to undertake a detailed phenotypic study to help to identify patients who may be suitable for therapeutic intervention. In addition, with the recent availability of advanced imaging modalities, further detailed phenotypic investigations will also be valuable in helping to probe the relationship between structure and function and may shed light on disease mechanisms.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04124185
Study type	Observational [Patient Registry]
Source	MeiraGTx UK II Ltd
Contact
Status	Completed
Phase
Start date	September 13, 2011
Completion date	May 18, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02610582` - Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia	Phase 1/Phase 2
Not yet recruiting	`NCT04041232` - PBA Use for Treatment of ATF6-/- Patients	Early Phase 1
Active, not recruiting	`NCT03278873` - Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3	Phase 1/Phase 2
Recruiting	`NCT02435940` - Inherited Retinal Degenerative Disease Registry
Completed	`NCT01846052` - Clinical and Genetic Characterization of Individuals With Achromatopsia	N/A
Active, not recruiting	`NCT01648452` - CNTF Implants for CNGB3 Achromatopsia	Phase 1/Phase 2
Completed	`NCT03001310` - Gene Therapy for Achromatopsia (CNGB3)	Phase 1/Phase 2
Active, not recruiting	`NCT02935517` - Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)	Phase 1/Phase 2
Completed	`NCT03758404` - Gene Therapy for Achromatopsia (CNGA3)	Phase 1/Phase 2
Active, not recruiting	`NCT02599922` - Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)	Phase 1/Phase 2